Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-SMART: COVID-19 Prevention and Treatment in Cancer
NCT04534725Phase 3Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of interferon alfa, selinexor and lenzilumab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 at 3 months, Incidence of any upper or lower community acquired respiratory viral infection at 3 months and 3 more. Started Dec 2020; status: completed.
02
Drugs
interferon alfaselinexorlenzilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04534725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534725.